The Next Frontier

With the mission of providing state-of-the-art education and training in the fast-emerging field of biopharmaceutical processing, the Jefferson Institute for Bioprocessing (JIB) formally opened its doors May 31 with a ribbon-cutting ceremony, tours and symposium.

Biologics represent about 40 percent of drugs in the pipeline with total global revenue of more than $200 billion annually, but pharmaceutical companies and manufacturers are limited by the lack of trained professionals in this field.

To meet these critical workforce needs, Jefferson established the first and only North American training institute in collaboration with industry leader National Institute for Bioprocessing Research and Training (NIBRT), using the GE Healthcare FlexFactory Platform to produce biopharmaceuticals.

“JIB is in the sweet spot between health care and innovation,” says Jefferson President Dr. Stephen K. Klasko in front of government officials and University leadership, faculty and trustees in attendance.

Today’s colleges and universities must ensure they prepare graduates for the future of work, says Dr. Mark L. Tykocinski, provost and executive vice president for academic affairs at Jefferson. At the same time, higher education needs to look beyond tuition and philanthropy to ensure its viability and vitality.

“The Jefferson Institute for Bioprocessing is the first example at Jefferson of an academic business unit—one that diversifies the generation of resources aimed at addressing the needs of a rapidly changing society,” says Dr. Tykocinski, the Anthony F. and Gertrude M. DePalma Dean of the Sidney Kimmel Medical College.

The growth of biologics represents a major industry shift from traditional chemical synthesis techniques. Biologic pharmaceuticals are manufactured in a living system, such as a microorganism, plant or animal cell, often using recombinant DNA technology. However, with a complex manufacturing process and lengthier regulatory approval process compared to traditional small-molecule drugs, biologics remain challenging to produce.

“It’s a personal pleasure and an honor to be here,” says Dominic Carolan, CEO of NIBRT, based in Dublin, Ireland. “This is an industry that has incredible growth. These are absolutely lifesaving products.”

JIB offers a broad range of training programs to advance the skills and knowledge of scientists, engineers and technicians who work in process development and biomanufacturing of biopharmaceuticals and biologics. Through the 25,000-square-foot flexible facility at Spring House Innovation Park in Lower Gwynedd, Pa., JIB provides tactile training by combining interactive presentations, workshops, and hands-on laboratory and pilot-scale experience.

In addition to open enrollment courses, JIB also offers customized training to meet industry needs with specialized courses developed with companies and delivered either at JIB or the company site. JIB will train approximately 2,500 bioprocessing professionals annually, with the first training session in July.

JIB’s roots began nearly three years ago when Mary Lynne Bercik ’90, fashion merchandising and management alumna and now an executive director at Merck, approached the University with the idea of working with NIBRT.

“She believed that Jefferson was perfect for this type of partnership because of the strengths that our legacy programs brought to the table—science and health on one side,  and design, engineering and business on the other,” says Kathy Gallagher, University chief operating officer.